(Q43758824)

26 November 2017

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. (English)

1 reference

26 November 2017

1 reference

1 reference

P A Netland

1

1 reference

26 November 2017

T Landry

2

1 reference

26 November 2017

E K Sullivan

3

1 reference

26 November 2017

R Andrew

4

1 reference

26 November 2017

L Silver

5

1 reference

26 November 2017

A Weiner

6

1 reference

26 November 2017

S Mallick

7

1 reference

26 November 2017

J Dickerson

8

1 reference

26 November 2017

M V Bergamini

9

1 reference

26 November 2017

S M Robertson

10

1 reference

26 November 2017

A A Davis

11

1 reference

26 November 2017

Travoprost Study Group

12

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Ophthalmology

26 November 2017

1 reference

26 November 2017

132

1 reference

26 November 2017

472-484

1 reference

26 November 2017

4

1 reference

The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

[3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

Racial differences in the cause-specific prevalence of blindness in east Baltimore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

7 January 2021

Blindness from Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901177-1

10.1016/S0002-9394(01)01177-1

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference